Event calendar

Event calendar

View recent presentations and learn more about upcoming events.
View of Banting 1 building - laboratory in Basel campus 10

Fourth quarter and full year 2024 results

January 31, 2025 | Basel, Switzerland

Media release: English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB)
Condensed financial report (PDF 0.5 MB)

Watch the webcast
Download the podcast (MP3 30 MB)
Download the presentation (PDF 4.7 MB)
Read the transcript 
Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)

Learn more
Upcoming events

Basel, Switzerland

 Las Vegas, USA

Toronto, Canada

London, UK

Frankfurt, Germany

 New York, USA

 New York, USA

Miami, USA

Interlaken, Switzerland

London, UK

London, UK

Basel, Switzerland

Basel, Switzerland

Event Calendar - 2024 Events

March 20, 2025
Zurich, Switzerland

March 12, 2025
Miami, USA

March 07, 2025
Basel, Switzerland

Visit the General Meetings section

March 04, 2025
Boston, USA

March 04, 2025
London, UK

January 14, 2025 
San Francisco, USA

Novartis CEO Vas Narasimhan presented at the J.P. Morgan Healthcare Conference.

Download the presentation (PDF 2.3 MB)

Download the podcast (MP3 18 MB)

December 09, 2024
Virtual event

Novartis 11th annual ESG investor event

Watch the webcast

Download the presentation (PDF 1.9 MB)

December 04, 2024
Miami, USA

November 21, 2024
London, UK

Read the media release

Watch the webcast

Download the webcast agenda (PDF 0.1 MB)

Download the speaker slides (PDF 0.8 MB)

Download the CEO presentation (PDF 1.2 MB)

Download the breakout slides (PDF 0.3 MB)

November 13, 2024
London, UK

November 12, 2024
Ranchos Palo Verdes, USA

November 12, 2024
Boston, USA

November 08, 2024
Zurich, Switzerland

October 29, 2024
Basel, Switzerland

Media release:
English (PDF 0.4 MB) | Deutsch (PDF 0.5 MB)
Interim financial report (PDF 0.6 MB)

Watch the webcast

Download the podcast (MP3 31 MB)

Download the presentation (PDF 6.8 MB)

Read the transcript

Novartis Q3 2024 impact and sustainability update (PDF 0.6 MB)

October 28, 2024
Virtual

Download the presentation (PDF 1.4 MB)

Watch the webcast

Download the podcast (MP3 30 MB)

September 26, 2024
Munich, Germany

September 25, 2024
Paris, France

September 18, 2024
London, UK

September 05, 2024
New York, USA

July 18, 2024
Basel, Switzerland

Media release:
English (PDF 0.5 MB) | Deutsch (PDF 0.5 MB) | Français (PDF 0.5 MB)

Interim financial report (PDF 0.5 MB

Watch the webcast

Download the podcast (MP3 34 MB)

Download the presentation (PDF 5.5 MB)

Read the transcript

Novartis Q2 2024 impact and sustainability update (PDF 0.9 MB)

June 27, 2024
Lyon, France

June 20, 2024
London, UK

June 19, 2024
London, UK

June 11, 2024
Miami, USA

June 06, 2024
New York, USA

June 02, 2024
Chicago, USA

Watch the webcast

Download the presentation (PDF 1.0 MB)

Read the media release: Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

May 29, 2024
New York, USA

May 23, 2024
Frankfurt, Germany

May 21, 2024
New York, USA

May 20, 2024
Brooklyn, USA

May 15, 2024
Toronto, Canada

May 15, 2024
Las Vegas, USA

April 23, 2024
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.4 MB)

Interim financial report (PDF 0.4 MB)

Watch the webcast

Download the podcast (MP3 30 MB)

Download the presentation (PDF 6.0 MB)

Read the transcript

Novartis Q1 2024 impact and sustainability update (PDF 1.4 MB)

March 26, 2024
Virtual

March 26, 2024
Paris, France

March 21, 2024
Zurich, Switzerland

March 06, 2024
Boston, USA

March 05, 2024
Basel, Switzerland

Visit the General Meetings section

February 28, 2024
London, UK

January 31, 2024
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.6 MB)

Download the podcast (MP3 34 MB)

Download the presentation (PDF 5.5 MB)

Read the transcript

Novartis Q4 2023 impact and sustainability update (PDF 0.6 MB)

2023 epidemiology data (PDF 1.1 MB)

January 08, 2024
San Francisco, USA 

Download the presentation (PDF 1.3 MB)

Download the podcast (MP3 18 MB)

Read the featured news

Event Calendar - 2023 Events

November 28, 2023
London, UK

Read the media release

Download the podcast (MP3 102 MB)

Access our interactive presentation (PDF 17 MB)

November 15, 2023
London, UK

November 13, 2023

Novartis 10th annual ESG investor event

Download the presentation (PDF 9.9 MB)
 

November 08, 2023
Miami, USA

October 24, 2023
Basel, Switzerland

Media release:
English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB) | Français (PDF 0.5 MB)

Interim financial report (PDF 0.6 MB)

Download the podcast (MP3 33 MB)

Download the interactive presentation (PDF 3.5 MB)

Novartis Q3 2023 Impact and Sustainability Update (PDF 1.0 MB)

October 24, 2023
Basel, Switzerland

Download the podcast (MP3 24 MB)

Download the presentation (PDF 1.0 MB)

October 10, 2023

Download the presentation (PDF 0.4 MB)

September 15, 2023 
Basel, Switzerland

Visit the General Meetings section

Sep 13, 2023
London, UK

Sep 12, 2023
New York, USA

September 06, 2023
Boston, USA

July 18, 2023
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Download the interactive presentation (PDF 3.4 MB)

Download the podcast (MP3 34 MB)

Read the presentation transcript

Novartis Q2 2023 Impact and Sustainability Update (PDF 0.3 MB)

June 29, 2023
Bordeaux, France

June 22, 2023
London, UK

June 21, 2023
London, UK

June 12, 2023
Dana Point, USA

June 08, 2023
New York, USA

Download the podcast (MP3 160 MB)

June 12, 2023
London, UK

Download the podcast (MP3 111 MB)

Read the media release

Download the presentation (PDF 11 MB)

June 04, 2023
Chicago, USA

Read the media release

Download the presentation (PDF 1.2 MB)

May 09, 2023
Las Vegas, USA

April 26, 2023

Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’ activities and the Coartem® brand from Sandoz to the Innovative Medicines Division, which were effective as of January 1, 2023. The 2022 updated segment financial reporting is provided in accordance with requirements of IFRS, and to aid comparability of 2023 quarterly and full year results for the segments and Corporate.

Download the presentation (PDF 0.4 MB)

April 25, 2023
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.3 MB)

Download the interactive presentation (PDF 3.4 MB)

Download the podcast (MP3 34 MB)

Read the presentation transcript

Novartis Q1 2023 Impact and Sustainability Update (PDF 1.9 MB)

March 14, 2023
Miami, USA

March 07, 2023
Basel, Switzerland

Visit the General Meetings section

March 07, 2023
Boston, USA

March 01, 2023
London, UK

February 21, 2023
Virtual

February 14, 2023
Virtual

February 08, 2023
Virtual

February 01, 2023
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Download the presentation (PDF 5.1 MB)

Download the podcast (MP3 45 MB)

Read the presentation transcript

Novartis ESG Update Q4 2022 (PDF 0.9 MB)

January 09, 2023
San Francisco, USA

Download the presentation (PDF 2.7 MB)

Download the podcast (MP3 18 MB)
 

 

Event Calendar - 2022 Events

December 13, 2022
Basel, Switzerland

Download the presentation (PDF 0.9 MB)

Download the podcast (MP3 24 MB)

Read the media release

December 07, 2022
London, UK

December 01, 2022
Paris, France

November 30, 2022
Basel, Switzerland

Download the presentation (PDF 1.6 MB)

 

November 16, 2022
London, UK

November 09-10, 2022
Palos Verdes, US

November 09, 2022
London, UK

October 25, 2022
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Interim financial report (PDF 0.5 MB)

Download the presentation (PDF 3.7 MB)

Download the podcast (MP3 40 MB)

Read the presentation transcript

Novartis ESG Update - October 31, 2022 (PDF 0.5 MB)

September 28, 2022
London, UK

September 21-22, 2022
Basel, Switzerland

Download the agenda (PDF 0.2 MB)

Download the interactive presentation (PDF 4.7 MB)

Download the speakers slides (PDF 0.5 MB)

Read the media release
 

September 14, 2022
London, UK

September 12, 2022
New York, USA

August 25, 2022
Basel, Switzerland

Download the podcast (MP3 28 MB)

Download the presentation (PDF 1.1 MB)

Read the media release: English | Deutsch

July 19, 2022
Basel, Switzerland

Media release:
English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)

Interim financial report (PDF 0.5 MB)

Download the presentation (PDF 2.9 MB)

Download the podcast (MP3 42 MB)

Read the presentation transcript

Novartis ESG Update - July 20, 2022 (PDF 0.4 MB)

June 23, 2022
London, UK

June 15, 2022
London, UK

June 14, 2022
Palos Verdes, USA

June 10, 2022
New York, USA

June 09, 2022
New York, USA

June 02, 2022
New York, USA

May 23-24, 2022
New York, USA

May 23, 2022
New York, USA

May 18, 2022
New York, USA

May 18, 2022
Virtual

May 11, 2022
Paris, France

April 26, 2022
Basel, Switzerland

Media release:
English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)

Interim financial report (PDF 0.4 MB)

Download the presentation (PDF 4.1 MB)

Download the podcast (MP3 40 MB)

Read the presentation transcript

Novartis ESG Update - April 27, 2022 (PDF 0.7 MB)

Reconciliation of 2021 results excluding Roche investment impacts (PDF 0.5 MB)

April 04, 2022

Download the presentation (PDF 2.8 MB)

Read the media release

Download the Novartis organizational structure (PDF 0.2 MB)

Executive Committee of Novartis (ECN)

Source URL: https://prod1.novartis.com/investors/event-calendar

List of links present in page
  1. https://prod1.novartis.com/investors/event-calendar
  2. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-media-release-en.pdf
  3. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-media-release-de.pdf
  4. https://prod1.novartis.com/sites/novartis_com/files/2025-01-interim-financial-report-en.pdf
  5. https://edge.media-server.com/mmc/p/7vboajm5/
  6. https://prod1.novartis.com/sites/novartis_com/files/2025-02/q4-2024-investor-presentation.mp3
  7. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-investor-presentation.pdf
  8. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q4-and-full-year-results-transcript
  9. https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2024-impact-and-sustainability-update.pdf
  10. https://prod1.novartis.com/investors/financial-data/quarterly-results
  11. #tabrecent-events-264806
  12. #tab2023-archive-139176
  13. #tab2022-archive-43351
  14. https://prod1.novartis.com/node/662281
  15. https://prod1.novartis.com/investors/shareholder-information/general-meetings
  16. https://prod1.novartis.com/sites/novartis_com/files/novartis-investor-presentation-jpm-2025-growth-story.pdf
  17. https://prod1.novartis.com/sites/novartis_com/files/2025-01/novartis-investor-presentation-jpm-2025-growth-story.mp3
  18. https://novartis.webcasts.com/starthere.jsp?ei=1689776&tp_key=9312b9a422
  19. https://prod1.novartis.com/sites/novartis_com/files/2024-12-novartis-impact-sustainability.pdf
  20. https://prod1.novartis.com/news/media-releases/novartis-upgrades-mid-term-guidance-and-highlights-deep-pipeline-core-therapeutic-areas-drive-long-term-growth
  21. https://edge.media-server.com/mmc/p/mfs4d9bz
  22. https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-agenda.pdf
  23. https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-speaker-slides.pdf
  24. https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-ceo-presentation.pdf
  25. https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-breakout-slides.pdf
  26. https://prod1.novartis.com/sites/novartis_com/files/q3-2024-media-release-en.pdf
  27. https://prod1.novartis.com/sites/novartis_com/files/q3-2024-media-release-de.pdf
  28. https://prod1.novartis.com/sites/novartis_com/files/2024-10-interim-financial-report-en.pdf
  29. https://edge.media-server.com/mmc/p/3hsrpsa4
  30. https://prod1.novartis.com/sites/novartis_com/files/2024-10/q3-2024-investor-presentation.mp3
  31. https://prod1.novartis.com/sites/novartis_com/files/q3-2024-investor-presentation.pdf
  32. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q3-transcript
  33. https://prod1.novartis.com/sites/novartis_com/files/novartis-q3-2024-impact-and-sustainability-update.pdf
  34. https://prod1.novartis.com/sites/novartis_com/files/2024-10-novartis-renal-portfolio-presentation.pdf
  35. https://edge.media-server.com/mmc/p/d4yyo26k
  36. https://prod1.novartis.com/sites/novartis_com/files/2024-10/2024-10-novartis-renal-portfolio-presentation.mp3
  37. https://prod1.novartis.com/sites/novartis_com/files/q2-2024-media-release-en.pdf
  38. https://prod1.novartis.com/sites/novartis_com/files/q2-2024-media-release-de.pdf
  39. https://prod1.novartis.com/sites/novartis_com/files/q2-2024-media-release-fr.pdf
  40. https://prod1.novartis.com/sites/novartis_com/files/2024-07-interim-financial-report-en.pdf
  41. https://edge.media-server.com/mmc/p/a2y6rkfr
  42. https://prod1.novartis.com/sites/novartis_com/files/2024-07/q2-2024-investor-presentation.mp3
  43. https://prod1.novartis.com/sites/novartis_com/files/q2-2024-investor-presentation.pdf
  44. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q2-transcript
  45. https://prod1.novartis.com/sites/novartis_com/files/novartis-q2-2024-impact-and-sustainability-update.pdf
  46. https://edge.media-server.com/mmc/p/3xi5zz7j/
  47. https://prod1.novartis.com/sites/novartis_com/files/2024-novartis-asco-investor-event-presentation.pdf
  48. https://prod1.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml
  49. https://prod1.novartis.com/sites/novartis_com/files/q1-2024-media-release-en.pdf
  50. https://prod1.novartis.com/sites/novartis_com/files/q1-2024-media-release-de.pdf
  51. https://prod1.novartis.com/sites/novartis_com/files/q1-2024-media-release-fr.pdf
  52. https://prod1.novartis.com/sites/novartis_com/files/2024-04-interim-financial-report-en.pdf
  53. https://edge.media-server.com/mmc/p/dngt7jjp
  54. https://prod1.novartis.com/sites/novartis_com/files/2024-04/q1-2024-investor-presentation.mp3
  55. https://prod1.novartis.com/sites/novartis_com/files/q1-2024-investor-presentation.pdf
  56. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q1-transcript
  57. https://prod1.novartis.com/sites/novartis_com/files/novartis-q1-2024-impact-and-sustainability-update.pdf
  58. https://prod1.novartis.com/investors/shareholder-information/general-meetings
  59. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-en.pdf
  60. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-de.pdf
  61. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-fr.pdf
  62. https://prod1.novartis.com/sites/novartis_com/files/2024-01-interim-financial-report-en.pdf
  63. https://prod1.novartis.com/sites/novartis_com/files/2024-02/q4-2023-investor-presentation.mp3
  64. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-investor-presentation.pdf
  65. https://prod1.novartis.com/investors/financial-data/quarterly-results/2023-q4-and-full-year-results-transcript
  66. https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2023-impact-and-sustainability-update.pdf
  67. https://prod1.novartis.com/sites/novartis_com/files/novartis-target-patient-populations-2023.pdf
  68. https://prod1.novartis.com/sites/novartis_com/files/2024-jpm-novartis-strategy-growth-update.pdf
  69. https://prod1.novartis.com/sites/novartis_com/files/2024-01/2024-jpm-novartis-strategy-growth-update.mp3
  70. https://prod1.novartis.com/news/jp-morgan-healthcare-conference-2024
  71. https://prod1.novartis.com/node/662281/printable/print
  72. https://prod1.novartis.com/node/662281/printable/pdf
  73. https://prod1.novartis.com/node/546201
  74. https://prod1.novartis.com/news/media-releases/novartis-upgrades-mid-term-sales-growth-guidance-showcases-its-differentiated-innovative-medicines-strategy-and-robust-pipeline-rd-day
  75. https://prod1.novartis.com/sites/novartis_com/files/2023-12/novartis-investors-r-d-day-2023.mp3
  76. https://prod1.novartis.com/sites/novartiscom/files/novartis-investors-r-d-day-2023.pdf
  77. https://prod1.novartis.com/sites/novartiscom/files/2023-11-novartis-investor-impact-health-equity.pdf
  78. https://prod1.novartis.com/sites/novartis_com/files/q3-2023-media-release-en.pdf
  79. https://prod1.novartis.com/sites/novartis_com/files/q3-2023-media-release-de.pdf
  80. https://prod1.novartis.com/sites/novartis_com/files/q3-2023-media-release-fr.pdf
  81. https://prod1.novartis.com/sites/novartis_com/files/2023-10-interim-financial-report-en.pdf
  82. https://prod1.novartis.com/sites/novartis_com/files/2023-10/q3-2023-investor-presentation.mp3
  83. https://prod1.novartis.com/sites/novartis_com/files/q3-2023-investor-presentation.pdf
  84. https://prod1.novartis.com/sites/novartis_com/files/novartis-q3-2023-impact-and-sustainability-update.pdf
  85. https://prod1.novartis.com/sites/novartis_com/files/2023-10/2023-novartis-esmo-call-presentation.mp3
  86. https://prod1.novartis.com/sites/novartis_com/files/2023-novartis-esmo-call-presentation.pdf
  87. https://prod1.novartis.com/sites/novartis_com/files/novartis-results-continuing-operations-october-2023.pdf
  88. https://prod1.novartis.com/investors/shareholder-information/general-meetings
  89. https://prod1.novartis.com/sites/novartis_com/files/q2-2023-media-release-en.pdf
  90. https://prod1.novartis.com/sites/novartis_com/files/q2-2023-media-release-de.pdf
  91. https://prod1.novartis.com/sites/novartis_com/files/q2-2023-media-release-fr.pdf
  92. https://prod1.novartis.com/sites/novartis_com/files/2023-07-interim-financial-report-en.pdf
  93. https://prod1.novartis.com/sites/novartis_com/files/q2-2023-investor-presentation.pdf
  94. https://prod1.novartis.com/sites/novartis_com/files/2023-07/q2-2023-investor-presentation.mp3
  95. https://prod1.novartis.com/investors/financial-data/quarterly-results/2023-q2-transcript
  96. https://prod1.novartis.com/sites/novartis_com/files/novartis-q2-2023-impact-and-sustainability-update.pdf
  97. https://prod1.novartis.com/sites/novartis_com/files/2023-06/sandoz-capital-markets-day-new-york.mp3
  98. https://prod1.novartis.com/sites/novartis_com/files/2023-06/sandoz-capital-markets-day-london.mp3
  99. https://prod1.novartis.com/news/media-releases/sandoz-presents-compelling-investment-proposition-standalone-company-capital-markets-day
  100. https://prod1.novartis.com/sites/novartis_com/files/2023-sandoz-capital-markets-day-presentation.pdf
  101. https://prod1.novartis.com/news/media-releases/novartis-kisqali-significantly-reduced-risk-recurrence-25-across-broad-population-patients-early-breast-cancer-clinically-meaningful-benefit-was-consistent-across-subgroups
  102. https://prod1.novartis.com/sites/novartis_com/files/2023-06-novartis-asco-presentation.pdf
  103. https://prod1.novartis.com/sites/novartis_com/files/novartis-2022-financials-updated-segment-reporting-april-2023.pdf
  104. https://prod1.novartis.com/sites/novartis_com/files/q1-2023-media-release-en.pdf
  105. https://prod1.novartis.com/sites/novartis_com/files/q1-2023-media-release-de.pdf
  106. https://prod1.novartis.com/sites/novartis_com/files/q1-2023-media-release-fr.pdf
  107. https://prod1.novartis.com/sites/novartis_com/files/2023-04-interim-financial-report-en.pdf
  108. https://prod1.novartis.com/sites/novartis_com/files/q1-2023-investor-presentation.pdf
  109. https://prod1.novartis.com/sites/novartis_com/files/2023-04/q1-2023-investor-presentation.mp3
  110. https://prod1.novartis.com/investors/financial-data/quarterly-results/2023-q1-transcript
  111. https://prod1.novartis.com/sites/novartis_com/files/novartis-q1-2023-impact-and-sustainability-update.pdf
  112. https://prod1.novartis.com/investors/shareholder-information/general-meetings
  113. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-media-release-en.pdf
  114. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-media-release-de.pdf
  115. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-media-release-fr.pdf
  116. https://prod1.novartis.com/sites/novartis_com/files/2023-02-interim-financial-report-en.pdf
  117. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-investor-presentation.pdf
  118. https://prod1.novartis.com/sites/novartis_com/files/2023-02/q4-2022-investor-presentation.mp3
  119. https://prod1.novartis.com/investors/financial-data/quarterly-results/2022-q4-and-full-year-results-transcript
  120. https://prod1.novartis.com/sites/novartis_com/files/environmental-social-and-governance-february-2023-update.pdf
  121. https://prod1.novartis.com/sites/novartis_com/files/2023-new-novartis-pure-play-innovative-medicines-company.pdf
  122. https://prod1.novartis.com/sites/novartis_com/files/2023-01/2023-new-novartis-pure-play-innovative-medicines-company.mp3
  123. https://prod1.novartis.com/node/546201/printable/print
  124. https://prod1.novartis.com/node/546201/printable/pdf
  125. https://prod1.novartis.com/node/126531
  126. https://prod1.novartis.com/sites/novartis_com/files/2022-12-13-iptacopan-ash-update-presentation.pdf
  127. https://prod1.novartis.com/sites/novartis_com/files/2022-12/2022-12-13-iptacopan-ash-update-presentation.mp3
  128. https://prod1.novartis.com/news/media-releases/novartis-presents-pivotal-phase-iii-apply-pnh-data-ash-demonstrating-investigational-oral-monotherapy-iptacopan-superiority-over-anti-c5
  129. https://prod1.novartis.com/sites/novartis_com/files/2022-11-novartis-investor-update-access-sustainability.pdf
  130. https://prod1.novartis.com/sites/novartis_com/files/q3-2022-media-release-en.pdf
  131. https://prod1.novartis.com/sites/novartis_com/files/q3-2022-media-release-de.pdf
  132. https://prod1.novartis.com/sites/novartis_com/files/q3-2022-media-release-fr.pdf
  133. https://prod1.novartis.com/sites/novartis_com/files/2022-10-interim-financial-report-en.pdf
  134. https://prod1.novartis.com/sites/novartis_com/files/q3-2022-investor-presentation.pdf
  135. https://prod1.novartis.com/sites/novartis_com/files/2022-10/q3-2022-investor-presentation.mp3
  136. https://prod1.novartis.com/investors/financial-data/quarterly-results/2022-q3-transcript
  137. https://prod1.novartis.com/sites/novartis_com/files/environmental-social-and-governance-october-2022-update.pdf
  138. https://prod1.novartis.com/sites/novartis_com/files/2022-novartis-meet-management-agenda.pdf
  139. https://prod1.novartis.com/sites/novartis_com/files/2022-09-meet-novartis-management-event-presentation.pdf
  140. https://prod1.novartis.com/sites/novartis_com/files/2022-09-meet-novartis-management-event-speakers.pdf
  141. https://prod1.novartis.com/news/media-releases/novartis-unveils-new-focused-strategy-underpinned-eight-potential-multi-billion-dollar-peak-sales-brands-deep-pipeline-meet-management-event
  142. https://prod1.novartis.com/sites/novartis_com/files/2022-08/2022-novartis-sandoz-spinoff-presentation.mp3
  143. https://prod1.novartis.com/sites/novartis_com/files/2022-novartis-sandoz-spinoff-presentation.pdf
  144. https://prod1.novartis.com/news/media-releases/novartis-announces-intention-separate-sandoz-business-create-standalone-company-way-100-spin
  145. https://prod1.novartis.com/news/media-releases/novartis-will-das-sandoz-geschaft-durch-eine-hundertprozentige-ausgliederung-als-eigenstandiges-unternehmen-abspalten
  146. https://prod1.novartis.com/sites/novartis_com/files/q2-2022-media-release-en.pdf
  147. https://prod1.novartis.com/sites/novartis_com/files/q2-2022-media-release-de.pdf
  148. https://prod1.novartis.com/sites/novartis_com/files/q2-2022-media-release-fr.pdf
  149. https://prod1.novartis.com/sites/novartis_com/files/2022-07-interim-financial-report-en.pdf
  150. https://prod1.novartis.com/sites/novartis_com/files/q2-2022-investor-presentation.pdf
  151. https://prod1.novartis.com/sites/novartis_com/files/2022-07/q2-2022-investor-presentation.mp3
  152. https://prod1.novartis.com/investors/financial-data/quarterly-results/2022-q2-transcript
  153. https://prod1.novartis.com/sites/novartis_com/files/environmental-social-and-governance-july-2022-update.pdf
  154. https://prod1.novartis.com/sites/novartis_com/files/q1-2022-media-release-en.pdf
  155. https://prod1.novartis.com/sites/novartis_com/files/q1-2022-media-release-de.pdf
  156. https://prod1.novartis.com/sites/novartis_com/files/q1-2022-media-release-fr.pdf
  157. https://prod1.novartis.com/sites/novartis_com/files/2022-04-interim-financial-report-en.pdf
  158. https://prod1.novartis.com/sites/novartis_com/files/q1-2022-investor-presentation.pdf
  159. https://prod1.novartis.com/sites/novartis_com/files/2022-04/q1-2022-investor-presentation.mp3
  160. https://prod1.novartis.com/investors/financial-data/quarterly-results/2022-q1-transcript
  161. https://prod1.novartis.com/sites/novartis_com/files/environmental-social-and-governance-april-2022-update.pdf
  162. https://prod1.novartis.com/sites/novartis_com/files/2022-04-reconciliation-of-2021-results-excluding-roche-investment-impacts.pdf
  163. https://prod1.novartis.com/sites/novartis_com/files/2022-04-novartis-new-organizational-model-presentation.pdf
  164. https://prod1.novartis.com/news/media-releases/novartis-announces-new-organizational-structure-accelerate-growth-strengthen-pipeline-and-increase-productivity
  165. https://prod1.novartis.com/sites/novartis_com/files/novartis-org-chart.pdf
  166. https://prod1.novartis.com/about/executive-committee
  167. https://prod1.novartis.com/node/126531/printable/print
  168. https://prod1.novartis.com/node/126531/printable/pdf